SCHEMBL2643783

SCHEMBL2643783

COCC1Cc2c(O)cc(C(=O)O)cc2O1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELAVL3 Q14576 1/20 0.41
PGAM1 P18669 2/20 0.39
TPMT P51580 2/20 0.39
DYRK1A Q13627 7/20 0.39
MMP2 P08253 7/20 0.39
MMP14 P50281 6/20 0.39
MMP7 P09237 5/20 0.39
BACE1 P56817 3/20 0.39
HSP90AB1 P08238 3/20 0.39
MET P08581 2/20 0.39
BCL2 P10415 2/20 0.39
PSMB5 P28074 2/20 0.39
SNCA P37840 2/20 0.39
PGD P52209 2/20 0.39
PKMYT1 Q99640 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
RECQL P46063 2/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2657238 0.83 DYRK1A (0.39) ELAVL3PGAM1DYRK1AMMP2MMP14
SCHEMBL2644805 0.81 XDH (0.34) TPMTKMT2ATDP1PTGS2ALDH1A1
SCHEMBL2644459 0.78 MEN1 (0.43) MEN1KMT2AHPGD
SCHEMBL11506396 0.77 TDP1 (0.53) ELAVL3PGAM1DYRK1AMMP2MMP14
SCHEMBL644201 0.75 NPC1 (0.43) KCNH2
SCHEMBL2643841 0.74 ALDH1A1 (0.41) ALDH1A1HPGDKCNH2TTR
SCHEMBL2644125 0.74 PTGS2 (0.38) PTGS2KCNH2TTR
SCHEMBL642185 0.73 HPGD (0.50) ELAVL3PGAM1DYRK1AMMP2MMP14
SCHEMBL2644248 0.72 HPGD (0.40) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL22978667 0.72 TDP1 (0.45) TPMTKDM4EMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 ELAVL3 4001/4885PGAM1 319/4885TPMT 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.